CPT code 0481T denotes an autologous biologic procedure in which a provider harvests and processes a patient’s white blood cells to create a concentrated protein solution that is injected into the same patient; imaging guidance may be used for harvesting and/or injection. This code captures a complex, procedure-based service bridging laboratory processing and image-guided clinical intervention and is relevant to specialties offering biologic therapies and regenerative medicine services.

Key payers covered in this analysis include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find a concise national perspective on how this service is billed and categorized, the clinical context for use, and the operational settings typically associated with the procedure. The publication highlights benchmark considerations for reimbursement and utilization, pertinent policy developments affecting coverage of autologous biologic injections, and clinical implications for providers and billing teams.

This summary equips revenue cycle and clinical leaders with the essential facts to understand CPT code 0481T, its role in autologous biologic interventions, and the national payer landscape that shapes access and payment for this service. Data not available in the input where specific payer rates, taxonomies, and diagnosis mappings would normally be provided.